Repros Therapeutics — Investor Presentation (July 2016)
40 slides from Repros Therapeutics's investor presentation, Jul 19, 2016
Slide 1: Enclomiphene (EnCyzix): A Mechanistically Consistent Approach to Secondary Hypogonadism
Enclomiphene ( EnCyzix ™) A Mechanistically Consistent Approach to the Treatment of Secondary Hypogonadism
Slide 2: Repros Disclaimer
Repros Disclaimer Any statements made by the Company that are not historical facts contained in these slides (or in any oral accompanying discussion) are forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to various risks, uncertai
Slide 3: Age-Related Hypogonadism
CM - 3 Age - Related Hypogonadism In recent years, use of testosterone therapies has increased markedly among middle - aged and elderly men for a controversial condition that the FDA calls “ age - related hypogonadism , ” also referred to as “ late onset hypogonadism , ” a condition which is typical
Slide 4: Prescription Claims for Testosterone Products
CM - 4 Prescription Claims for Testosterone Products Nguyen et al N Eng J Med 2015 73% 9% 3%
Slide 5: Prevalence of Overweight and Obesity
CM - 5 Prevalence of Overweight and Obesity Global Burden of Disease Study 2013 (Ng et al Lancet 2014) Prevalence (%) 70 60 50 40 3 0 20 10 0 2 - 9 10 - 19 20 - 29 30 - 39 40 - 49 50 - 59 60 - 69 70 - 79 ≥80 Age (years) 29.0 39.4 32.0 0 20 40 60 20-39 Years 40-59 Years ≥60 Years Percent CDC (Ogden,
Slide 6: Categorizing Gonadal Status by Testosterone and LH
CM - 6 0 20 40 60 80 LH (U/L) 0 10 20 30 40 50 Total Testosterone (nmol/L) Primary Hypogonadism Low T, high LH n=52 (1.7%) n = 3219 40 – 80 yr Categorizing Gonadal Status by Testosterone and LH Eugonadal Normal T and LH Compensated ‘Hypogonadism ’ Normal T, high LH Secondary Hypogonadism Low T, norm
Slide 7: BMI and Age: Different Effects on Hormones
CM - 7 EMAS Wu, JCEM 2008 BMI and Age: Different Effects on Hormones Increasing BMI is associated with progressively lower testosterone levels, independent of age Increasing age is associated with progressively higher LH levels, independent of BMI Testosterone ( nmol /L) LH (U/L)
Slide 8: Risk Factors
CM - 8 Risk Factors Age ( yrs ) BMI ≥ 25 - <30 kg/m 2 BMI ≥ 30 kg/m 2 Smoking ( current) Alcohol ( frequent) Co - morbidity ( ≥ 1) 0 5 10 15 *** *** * Adjusted Relative Risk Ratio Secondary Obesity Related Hypogonadism EMAS Tajar, JCEM 2010 0 5 10 15 *** Hypogonadism of Aging * p<0.05 *** p<0.001 Pr
Slide 9: Mechanisms Controlling Testicular Function
CM - 9 Mechanisms Controlling Testicular Function 9 Hypothalamus Pituitary Androgen Effects Fertility Estradiol (E 2 ) DHT GnRH LH FSH + + + + - T + Testis + - Leydig cells Sertoli cells Testosterone ( T) Spermatogenes is T T
Slide 10: Exogenous Testosterone for Secondary Hypogonadism
CM - 10 Exogenous Testosterone for Secondary Hypogonadism 10 Hypothalamus Pituitary Androgen Effects Fertility Estradiol (E 2 ) DHT GnRH LH FSH + - T + Testis Leydig cells Sertoli cells Testosterone ( T) Spermatogenes is T T Exogenous Testosterone Suppresses the HPG Axis
Slide 11: What Do We Know About Men Seeking Treatment for Hypogonadism?
CM - 11 So What Do We Know About the Current Group of Men Seeking Treatment for Hypogonadism? The majority are secondary hypogonadal and are fertile Confirmatory diagnosis not practiced in the US No studies conducted by hormone replacement sponsors to assess impact on spermatogenesis “But th
Slide 12: Enclomiphene Yields Meaningful Reproducible Outcomes
ZA - 304 & ZA - 305 Results Enclomiphene Yields Meaningful Reproducible Outcomes Study ZA - 304 (p - values Treatment vs Enclomiphene) ZA - 305 (p - values Treatment vs Enclomiphene) Treatment Enclomiphene Androgel Placebo Enclomiphene Androgel Placebo N 41 43 45 44 42 41 Age (SD) 49.1 (7.4) 47.4 (7
Slide 13: How Enclomiphene Works
How Enclomiphene Works Enclomiphene blocks estrogen at the level of the H - P axis increasing LH levels which in turn increases endogenous production of T 0 1 2 3 4 5 6 7 Enclomiphene LH Androgel LH Median LH ( mIU /mL) Impact on LH in 16 Wk Study ZA - 304 Baseline End of Study 0 50 100 150 200 250
Slide 14: Enclomiphene maintains normal diurnal rhythm
OT - 14 0 100 200 300 400 500 600 0 2 4 6 8 10 12 14 16 18 20 22 24 Mean Testosterone (ng/ dL ) Hours Post Dosing Phase 3 24 Hr Serial Testosterone Enclomiphene (n=298) AndroGel (n=75) Placebo (n=158) Unlike Topical Testosterone Administration There is No Temporal Relationship Between Time of Enclom
Slide 15: No Negative Effects on Spermatogenesis Unlike Exogenous T
Enclomiphene Exhibits No Negative Effects on Spermatogenesis Unlike Exogenous T -70 -60 -50 -40 -30 -20 -10 0 10 20 % Change from Baseline Impact on Sperm Concentration After 16 Wks Treatment ZA - 304 Enclomiphene Androgel Placebo 0 10 20 30 40 50 60 % of Oligospermic Subjects % of Subjects Becoming
Slide 16: Percent Change in Testicular Volume
5.1 6.8 - 6.8 - 2.2 10.7 5.4 -8 -6 -4 -2 0 2 4 6 8 10 12 ZA-304 ZA-305 Mean Percent Change from Baseline Enclomiphene AndroGel Placebo Percent Change in Testicular Volume by Orchidometry vs. AndroGel p = 0.0074 vs. AndroGel p = 0.0224 n = 41 43 45 44 42 41
Slide 17: Enclomiphene Averages >77% of Men in Normal Range
Enclomiphene Averages > 75 % of Men Studied in Normal Range • 10 studies conducted with durations up to 1 year • Table determined as LOCF for morning T Study Subjects Receiving Enclomiphene Study Duration % Morning T in Normal Range (LOCF) ZN - 018 22 2 Wks. 77.3 ZA - 003 97 3 Mo. 63.9 ZA - 203 57 3
Slide 18: Is There Anything Else to Worry About If I Take T?
CM - 18 “So is there anything else to worry about if I take T?” “I don’t want to have any more kids” You have a reversible disorder if you are willing to make a lifestyle change If you start taking testosterone you may need to take it for the rest of your life
Slide 19: Obesity Related Hypogonadism is a Reversible Disorder
Obesity Related Hypogonadism is a Reversible Disorder Treatment with Exogenous T “May require lifelong therapy” (Bayer abstract quote) Camacho et al. European Journal of Endocrinology 2013 n = 2395, *p<0.05, **p<0.01 Reported 15% Wt. Loss over 6 yrs. Source: Bayer - Schering Registry Study
Slide 20: Proof of Concept Diet & Exercise Study in Obese Hypogonadal Men
Phase 2 Proof of Concept “Diet & Exercise” Study in Obese Hypogonadal Men - Baseline Findings Screen 98 to enroll 50 15 Month Study • Enrollment (n=50 in 5 weeks @ 5 sites) • Demographics ( stdev ) – Age: 43.3 (9.2) – BMI: 36.8 (3.2) – Waist: 46.9” (4.1) – % Body Fat: 38.1 (5.2) • Hormonal Status –
Slide 21: Interim Month Data
Interim 3 Month Data ZA - 205 31 32 33 34 35 36 37 38 39 Bl 3 mo 6 mo 9 mo 12 mo 15mo BMI BMI Over Time 12.5 mg 25 mg pbo 0 50 100 150 200 250 300 350 400 450 Scr BL 3 mo 6 mo 9 mo 12 mo 15 mo Morning T (ng/ dL ) Morning T Over Time 12.5 mg 25 mg pbo Commercial diet ends at 6 months. Personal traine
Slide 22: Conclusions: Clinical Implications
CM - 22 Conclusions: Clinical Implications Diagnostic differentiation of secondary from primary hypogonadism is essential – measure T and LH – The commonest form of T deficiency in ‘aging’ men is Secondary Hypogonadism associated with obesity (independent of aging) due to reversible functional sup
Slide 23: Why Not Just Use Clomid?
Why Not Just Use Clomid ? Enclomiphene (Patented) Trans Isomer (Pure Estrogen Antagonist) of Clomiphene Commercial Clomid (60% Trans, 40% Cis) 0 20 40 60 80 100 0.01 1 100 10000 % Concentration ( nM ) Estrogen Receptor Binding Affinity zu en Trough Concentration of Enclomiphene In Serum at Steady St
Slide 24: Clomiphene Isomer Concentrations
25 mg Daily Clomiphene Administration Isomer Concentrations (n=15 subjects) 0 10 20 30 40 50 60 70 80 90 ng/mL in serum ng/ml Isomer Concentration after 25 mg Clomid Dose at Steady State Zuclomiphene Enclomiphene Clomid approximately 60 - 70% enclomiphene Zuclomiphene accumulates Long term safety no
Slide 25: Enclomiphene and Zuclomiphene Accumulate Differently in Tissues
Enclomiphene and Zuclomiphene Clear and Accumulate Differently in Different Tissues 0 10000 20000 30000 40000 50000 60000 70000 80000 4 hrs post dose 24 hrs post dose Change in Tissue Concentration After Single 20 mg Dose of 14 C Labeled Drug to a Mouse (ng/gm of tissue) Zu Lymph Nodes En Lymph Node
Slide 26: Enclomiphene and Zuclomiphene Accumulate Differently in Tissues
Enclomiphene and Zuclomiphene Clear and Accumulate Differently in Different Tissues 0 1000 2000 3000 4000 5000 6000 7000 8000 4 hrs post dose 24 hrs post dose Change in Tissue Concentration After Single 20 mg Dose of 14 C Labeled Drug to a Mouse (ng/gm of tissue) Zu Eyes En Eyes Zu Pigmented Skin En
Slide 27: Impact of 90 Day Administration on Organ Size in Mice
0 0.5 1 1.5 2 2.5 Testes Kidney Percent Body Weight Placebo 4 mg ENC 40 mg ENC 4 mg ZU 40 mg ZU Both doses of zuclomiphene , p value < 0.03 compared to controls for both organs Impact of 90 Day Administration of 4 & 40 mg/kg of Either Enclomiphene or Zuclomiphene to Male Mice (n=15/group) Both Doses
Slide 28: Enclomiphene Advantages vs Approved Hormone Replacement
Enclomiphene Exhibits Unique Profile with Numerous Advantages vs Approved Hormone Replacement • The Enclomiphene Advantages – Oral – Not controlled substance, cannot be abused – No supernormal levels of T achieved – No transference risk – Restores normal function (no loss of testicular function ) –
Slide 29: Size of Overweight and Obese US Population
Size of Overweight and Obese US Population It is more than a sex issue 83,740,000 Males Age 20 - 60 58,620,000 Overweight or Obese 28,470,000 Metabolic Syndrome 1,700,000 Symptomatic (libido, etc.) Overweight or Obese Estimates based on CDC, EMAS and Sponsor Data
Slide 30: Enclomiphene Regulatory Status
Enclomiphene Regulatory Status • NDA filed with FDA – Treatment of secondary hypogonadism in overweight men – FDA cancelled public Advisory Committee Meeting citing use of CLIA certified lab did not meet rigorous guidance for pharmacokinetic data – Enclomiphene is not testosterone • Enclomiphene pha
Slide 31: Proellex
Proellex Addressing significant unmet female reproductive disorders
Slide 32: Uterine Fibroids
Uterine Fibroids • Benign, monoclonal, hormone sensitive, smooth muscle tumors of the uterus • Most common tumor of the female reproductive tract – Heavy bleeding / anemia – Abdominal pressure / pain / urinary frequency • Affect 20 - 77% of women age 35 – 55 • 600,000 hysterectomies conducted annual
Slide 33: Current Clinical Activity Uterine Fibroids
Current Clinical Activity Uterine Fibroids • Vaginal Administration • Phase 2b 45 subjects 3 arm placebo controlled study • Two 18 week treatment periods separated by an off drug interval with 5 menstrual cycle follow - up • Type C meeting with FDA anticipated late 2016 • Low Dose Oral Administratio
Slide 34: Current Clinical Activity Uterine Fibroids cont'd
Current Clinical Activity Uterine Fibroids cont’d • Study Endpoints • Primary endpoint: Induction of Amenorrhea • Secondary endpoints : – UFSQoL , – Fibroid Size by MRI • Safety » DEXA » Endometrial effects
Slide 35: Impact of Proellex Treatment of Uterine Fibroids
Impact of 18 Weeks Proellex Treatment of Uterine Fibroids 58.3 46.2 80.0 80.0 0.0 18.2 0 10 20 30 40 50 60 70 80 90 6 mg Vaginal 12 mg Vaginal 6 mg Oral 12 mg Oral Placebo Vaginal Placebo Oral Subjects with Amenorrhea (%) - 27.3 - 13.4 - 13.5 - 40.0 3.6 3.5 -45 -40 -35 -30 -25 -20 -15 -10 -5 0 5 10
Slide 36: Endometriosis
• Definition: the presence of epithelial and stromal endometrial cells outside of the uterine cavity • Complaints of infertility or pregnancy loss • Pelvic pain/back pain • Dyspareunia (pain during sex) • Dysmenorrhea (menstrual cycle cramps) Endometriosis • 5% of women of reproductive age • Estimat
Slide 37: Proellex Eliminates Pain and Need for Analgesics in Endometriosis
Proellex Eliminates the Pain and Need for Analgesics to Control the Pain of Endometriosis 0 10 20 30 40 50 60 70 Placebo Proellex 25mg Proellex 50 % of Baseline Pain via BBSS Assessment p - value versus placebo 25 mg = 0.001 50 mg = 0.017 55.5 22.2 13.6 0 10 20 30 40 50 60 70 80 90 100 Placebo 25mg
Slide 38: Interim ZPE-202 Assessment
0 2 4 6 8 10 12 14 Baseline 18 weeks Days Mean Sum of Daily Menstrual Pain (28 days) Placebo Proellex 0 5 10 15 20 25 30 35 Baseline 18 Weeks Number of Pain Pills Taken Total Number of Pain Pills (28 days) Placebo Proellex Interim ZPE - 202 Assessment 18 Weeks of Treatment Placebo n=6, Proellex n=15
Slide 39: Proellex Clinical Goals
Proellex Clinical Goals • Confirm Phase 3 requirements with FDA • Uterine Fibroids: Fourth Quarter 2016 • Endometriosis: First Quarter 2017 • Completed Proellex NDA components • Pre - clinical complete (including 2 carcinogenicity studies) • Manufacturing complete (API sourced, stable final drug pro
Slide 40: Financial Summary
Financial Summary • Cash and equivalents: (unaudited June 30, 2016) $12.5 M • Cash used in 2016 through June 30, 2016 : $8.9 M • Cash runway: Q1 2017 • Current shares outstanding: 24.3 M shares
Repros Therapeutics — Investor Presentation (July 2016) on 6ix